L.A. County Public Health Covid-19 Report: 58 New Deaths, 2,780 New Positive Cases

On Sunday, the Los Angeles County Department of Public Health reported 58 new deaths from Covid-19, along with 2,780 new positive cases.

The number of deaths and confirmed cases reported today may reflect delays in weekend reporting. But today’s tallies bring the County to a total of 30,356 deaths and 2,782,953 positive cases.

1,391 County residents are hospitalized with Covid-19 at time of reporting. The percentage of those patients that are in the ICU was not made clear. Covid test results have now been made available to more than 11,354,000 people, with 22% testing positive. Today’s rolling 7-day average of those testing positive is 3.27%.

Must Read Stories

‘Coming 2 America’, ‘SNL’ Lead Winners At Make-Up Artists & Hair Stylists Guild Awards

Holiday 4-Day Box Office Overperforms: ‘Uncharted’ Mines $51M, ‘Dog’ Laps Up $18M

Academy Axes Oscar Ticket Lottery; #OscarsFanFavorite News: Notes On The Season

Special Report: Russian Propaganda Battle Underway In Ukraine As Possible Invasion Looms

Read More About:

‘Billions’ Season 6, Episode 5 Recap: All in the Family

This week, the ties that bind are feeling extra tight for Chuck, Prince and Scooter.

By Sean T. Collins

What’s on TV This Week: ‘Frederick Douglass: In Five Speeches’ and Awards Shows

A new documentary about Frederick Douglass debuts on HBO. And both the Screen Actors Guild Awards and the N.A.A.C.P. Image Awards air this weekend.

By Gabe Cohn

SAF-HOLLAND FY Preliminary Adj. EBIT Increases

SAF-HOLLAND SE, a supplier of trailer and truck components, reported that its preliminary adjusted EBIT for fiscal year 2021 increased to around 93 million euros from 58.8 million euros in the previous year.

Annual group sales were around 1.247 billion euros, up 30% from the prior year, due to strong customer demand. Adjusted for exchange rate effects, sales increased by around 32% to about 1.265 billion euros.

SAF-HOLLAND expects a positive market environment in 2022. However, the high cost burden, particularly in the first quarter 2022, will be a challenge.

Almirall Posts Net Loss In FY21, Core EBITDA Up; Sees Weak EBITDA, Core Net Sales Growth In FY22

Almirall, S.A. (ALM), a Spanish biopharmaceutical company, on Monday reported that its fiscal 2021 net loss was 40.9 million euros, mainly due to impairment charges.

Normalised net income was 81.4 million euros, compared to 95.1 million euros last year.

EBITDA edged down 1.1 percent from last year to 235.6 million euros. Core EBITDA, excluding AstraZeneca contribution, climbed 17 percent year-on-year to 211.3 million euros. The strong operational performance was driven by the positive contribution from growth drivers and strong performance of the EU dermatology portfolio

Total revenues reached 836.5 million euros, up 2.7 percent from last year’s 814.5 million euros. Net sales grew 2.5 percent to 827.2 million euros, driven by positive contribution from growth drivers and a strong EU dermatology performance.

Core net sales reached 809.8 million euros, a 7.2 percent year-on-year increase.

Further, the company said a dividend proposal of 0.19 euro per share will be submitted at the next Annual General Meeting on May 6.

Looking ahead for fiscal 2022, the company projects core net sales growth of mid-single-digit and total EBITDA of 190 million euros to 210 million euros.

Hammerson In Talks With Redical On Sale Of Victoria Gate&Victoria Quarter Shopping Centres

Property development and investment company Hammerson plc (HMSO.L) Monday confirmed that it is in discussions with entities related to Redical Holdings AG on terms for a possible sale of its Victoria Gate and Victoria Quarter shopping centres.

Responding to recent press speculation, the company confirmed the pricing under discussion is 120 million pounds, which would represent a class 2 transaction.

Hammerson said its strategy remains to realign the portfolio to focus on prime urban estates through disposals of non-core assets, to strengthen the balance sheet, and to re-cycle capital into its core portfolio and its development pipeline.

However, there can be no certainty that a transaction will take place. The company will provide a further announcement if appropriate.

Dechra Pharma H1 Profit Climbs, Lifts Dividend; Says Trading At H2 Start Strong – Quick Facts

Dechra Pharmaceuticals PLC (DPH.L) reported Monday that its first-half profit before taxation grew to 53.4 million pounds from last year’s 35.4 million pounds. Earnings per share were 37.38 pence, up 74.3 percent from 21.44 pence a year ago.

Underlying profit before taxation was 90.5 million pounds, compared to 75.1 million pounds. Underlying earnings per share were 64.01 pence, up from 54.28 pence last year.

EBITDA grew 15 percent to 101.3 million pounds from 88.2 million pounds a year ago.

Revenue for the period grew 10.9 percent to 332.4 million pounds from last year’s 299.8 million pounds. Revenues climbed 15.9 percent at constant currency rates.

Further, the Board declared an interim dividend of 12.00 pence per share, a growth of 8 percent on the prior period. The dividend will be payable on April 7 to shareholders on the Register at March 4.

Looking ahead, the company noted that trading at the start of the second half remains strong, especially in major markets which are returning to historic levels of growth as they normalise following the diminishing influence of COVID-19.